Advertisement
Trending - Altmetric
-
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models
-
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
-
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer
-
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer